• 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>行业动态>全球纳米生物技术研究报告

    江苏体彩网: 全球纳米生物技术研究报告

    互联网2009年5月14日 18:10 点击:1770

    时时彩网络平台 www.qlgr.net This report analyzes the worldwide markets for Nanobiotechnology in US$ Million. The major product segments analyzed are Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, and Nanotubes and Fullerenes), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 91 companies including many key and niche players worldwide such as Alnis Biosciences, Inc., American Pharmaceutical Partners, Inc., Biosante Phosphate Pharmaceuticals, Inc., Capsulution NanoScience AG, Carbon Nanotechnologies, Inc, C Sixty, Inc, Dendritic Nanotechnologies, Inc., Dendritech, Inc, Elan Pharmaceuticals, Flamel Technologies, Inc, iMedd, Inc., Nanospectra Biosciences, Inc., Nanophase Technologies Corporation, Nano-C, Inc., Nanocyl SA, Nanolab Systems Ltd, Nanosphere, Inc., Nanotherapeutics, Inc., Nanosys, Inc., PSiVida Ltd, Quantum Dot Corp, Starpharma Holdings Ltd, Sigma Aldrich Company, and Triton Biosystems, Inc.

    Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
     

    目录及图表

    I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

    II.
    1. Industry Overview II-1
    A Curtain Raiser II-1
    What’s The Obsession With Size? II-2
    Why Analysis at the Cellular Level is Important? II-2
    Lessons from Nature II-3
    Where Conventional Molecular Science Falls Short Nanobio
    Steps In II-3
    Conclusions II-3
    Dawn Breaks On Nanobiotechnology II-4
    Demystifying the Intriguing World of Nanobiotech II-4
    Nanoparticles: The Foundation of Nanobiotechnology II-5
    A Meeting Place of Medicine’s Best Solutions II-5
    Challenges II-6
    Nanotechnology Boom Echoes Downstream II-7
    Honey, I Shrunk the World! II-7
    Nanotechnology & Biology Tie the Knot: “Two to Tango” II-8
    Nanobiotechnology: The Next Battlefield II-8
    The Promise of Nanobiotechnology II-9
    Biological Weaponries Against Diseases Come in Small Packages II-9
    Proffered Benefits of Nanobiotechnology II-10
    Opportunity & Beyond II-11
    Nanobiotechnology
    Will it Live Up to the Expectations? II-11
    The Future of Nanobiotechnology: Shape of Things to Come II-12
    Nanobiotechnology: The Outer Limits II-12
    Futuristics: A Rumination II-12
    Nanobiotechnology In the Year 2015 II-13
    Field of Nanodiagnostics II-13
    Field of Regenerative Medicine II-13
    Field of Targeted Drug Delivery II-13

    2. Market Dynamics II-14
    Short Market Sizzlers II-14
    Consolidation to Speed Up in Nano-Enabled Delivery Systems
    Market II-14
    Dearth of Blockbuster Drugs in Pipeline Sparks Interest in
    Nanobio II-15
    Demand for Novel Products Complements the Exuberant Outlook II-15
    Public & Private Investment Pep Up the Market II-15
    The Regulatory Framework Evolves with the Technology II-15
    Nanomaterials & Nanoparticles Witness Robust Activity II-15
    Quantum Dot Patents Pose Legal Tangles II-16
    Colloidal Quantum Dots Prices Poised to Scale Down in Long Run II-16
    Miniaturized Liquid Handling Becomes Progressive II-16
    Unrealistic Expectations Exert Pressure On the Market II-17
    High Material Costs Put a Spoke in the Market’s Growth II-17
    Below Par Involvement from Pharma Biggies Limits Growth II-17
    Lack of De Facto Standards: A Challenge to Reckon With II-18
    Loosely Defined Safety Standards Creates a Niggling Worry II-18

    3. Industry Issues, Challenges & Controversies II-19
    Embroilment Over Ethical Issues II-19
    Social Relevance II-19
    Economic Relevance II-20
    Major Challenges Confronting the Industry II-21
    Commercial Exploration: A Treacherous Voyage II-21
    Dendrimers Commercialization
    An Uphill Task II-22
    High Production Costs and Development Complexity II-22
    Availability of Advanced Technology Alternatives II-22
    No Defined Framework to Judge New Product’s Safety and Efficacy II-23

    4. Industry Structure & Investment Patterns II-24
    Industry Structure: A Quick Primer II-24
    A Dissection of Select Segments II-24
    Nanoparticles II-24
    Nanotubes and Fullerenes II-25
    Dendrimers II-25
    A Peek Into the Regulatory Framework II-25
    United States II-26
    Europe II-26
    What’s Grooming Nanobiotech into an Investment High Street? II-26
    Interest Ignited by Nanotechnology II-26
    Tracking Investment Patterns in Nanobiotechnology II-27
    Interest in Nanobiotechnology Spills Over II-27
    Patent Expiration Sends the Popularity Index Spiraling II-28
    Drawing Significant Venture Capital Funds II-28
    Table 1: Venture Capital Funding in Nanobiotechnology as
    Compared to Other Types of Nanotechnology: A Peek into
    Substantiating Numerics Taking the US Market as a
    Demonstrative Example II-28
    Swelling Government Grants II-29
    The State of Public Sector Funding II-29
    Table 2: Nanobiotechnology Market in Select Regions (2004):
    Percentage Breakdown of Public Sector Funding by Country -
    South Korea, Taiwan, China, Australia, Canada, and Others
    (includes corresponding Graph/Chart) II-30
    A Closer Look at Regional Nano Efforts II-30
    United States: Unraveling the Country’s Edge II-30
    Europe: Hot On the Heels of the US II-31
    Germany II-31
    France II-31
    United Kingdom II-31
    Scandinavia II-32
    Table 3: European Nanobiotechnology Market (2003 & 2004):
    Percentage Breakdown of Public Sector Funding by Leading
    Region/Country
    European Commission, Germany, France, UK,
    and Others (includes corresponding Graph/Chart) II-32
    Japan: A Noteworthy Region II-32

    5. Nanobio’s Epochal Strides In Modern Medicine II-33
    A Primer II-33
    Impact on Drug Delivery Systems II-33
    Benefits Offered II-34
    Drug Encapsulation II-34
    High Level of Specificity II-35
    Increase in Drug Solubility and Uptake II-35
    Greater Usage Flexibility II-35
    Impact On Molecular Diagnostic Imaging II-35
    Seeing The Unseen II-36
    Impact On Pharmaceutical Drug Formulations II-36
    Impact On Therapeutics II-37
    Silver Nanoparticles as Effective Antimicrobial Agents II-37
    Modern Day Nanomedicine: A Current Scenario II-38
    Nanomedicine: The Cynosure of All Eyes II-38
    Drug Delivery Systems Epitomized by Nanomedicine II-39
    Targeted NanoDrug Delivery & Release II-40
    A Peek Into Potential Nanobio Enabled Drug Carriers II-41
    Micelles II-41
    Liposomes II-41
    Dendrimers & Liquid Crystals II-41
    Nanoparticles II-41
    Polymeric Nanoparticles II-42
    Hydrogels II-42
    Molecularly Imprinted Polymers II-42
    Microelectromechanical Systems (MEMS) II-42
    Nanosuspensions II-42
    Fullerenes: A Platform for GenX Drug Delivery II-43
    Types of Nano-Based Drug Delivery Systems, Related
    Materials, and Structures II-43
    Dynamics of Regenerative Medicine II-44
    Tissue Engineering and Restorations II-45
    Nanotechnology Enabled Diagnostics II-45
    Promised Path Breaking Applications in Molecular Diagnostics
    & Imaging II-46
    In-Vitro Diagnostics II-47
    In-Vivo Diagnostics II-47
    Nanoprobes & Implantable Devices in In-vivo Imaging II-48
    Nanocomposites in Molecular Labeling & Diagnostics II-48
    Laboratory-on-a-Chip
    A Revolutionary Technology in
    Biomolecular Detection II-49
    Biosensors
    Heralding New Opportunities in Molecular
    Diagnostics II-49
    Despite Huge Potential Key Hurdles Remain in
    Commercialization II-50
    Magnetic Nanoparticles for Imaging Applications in MRI II-50
    Dendrimers Promise Milestone Applications in MRI II-50
    Conclusions II-51
    Gauging the Real World Impact of Nanobiotech On Cancer: A
    Case Study II-51
    Quantum Dots Cock a Snook at Traditional Anti-Body Labeling
    Agents II-52
    Chemotherapeutic Reengineering & Gene Therapy: New
    Treatment Regimes II-52
    Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis II-53

    6. Technology Overview II-54
    Nanotechnology: An Introduction II-54
    A Revolution in the Making II-54
    Nanobiotechnology: An Exposition II-55
    Nanobiotechnology & Medicine II-55
    Nanobiotechnology & Biofuels II-55
    Global Nanobiotechnology Market (2005): Major Products II-56
    Global Nanobiotechnology Market (2005): Major Products Under
    Development II-56
    Analysis of Major Technology Segments II-57
    Nanomaterials II-57
    Nanoparticles II-57
    Nanoparticles in Labeling or Bio Tagging II-58
    Nanoparticles as Biomarkers II-58
    Classification of Nanoparticles II-58
    Solid Nanoparticles II-58
    Solid Lipid Nanoparticles II-59
    Calcium Phosphate Nanoparticles II-59
    Dendrimers II-59
    Dendrimers as Templates for Synthesis of Hybrid
    Nanostructures II-59
    Nanocomposites II-60
    Lamellar Nanocomposites II-60
    Nanostructured Materials and Membranes II-60
    Nanotubes and Fullerenes II-61
    Other Nanomaterials II-61
    Nanoshells II-61
    Nanohorns II-61
    Nanocapsules II-61
    Nanodevices II-62
    Nanotools II-62
    Select Nanotools II-62
    Atomic Force Microscopes II-62
    Hot Embossing Lithography II-63
    Dip-Pen Nanolithography II-63

    7. Global Research Centers and Institutions II-64
    Centre for Biologic Nanotechnology (USA) II-64
    Centre for Biological and Environmental Nanotechnology (USA) II-64
    Institute of Bioengineering and Nanotechnology (Singapore) II-64
    The Nanobiotechnology Center (USA) II-65
    The Tyndall National Institute (Ireland) II-65

    8. Research & Technology Effervescence II-66
    Dendritic NanoTechnologies Develops Novel Priostar™ Dendrimer
    Technology II-66
    Scientists Develop Novel DNA Buckyballs for Drug Delivery
    Applications II-66
    Nanotechnology Creates Hopes for Artificial Kidneys II-66
    Chinese Scientists Develop Novel Drug Delivery System II-66
    Scientists Attach Nanograins to Iron Oxide Nanoparticles for
    Drug Delivery II-67
    Researchers Employ Nanotubules to Diffuse Cancer Cells II-67
    Scientists Develop Innovative Nanoparticles for Cancer Treatment II-67
    Nanobiotech Companies Close in on Developing Avian Flu Vaccine II-68
    Silver Nanoparticles Show Promise Against HIV-1 Virus II-68
    Nanoparticles Prove Highly Active Against Water Contaminants II-68
    Nanobiotechnology Offers Major Breakthrough in New HIV Drug
    Development II-68
    Scientists Develop Innovative Nanoparticles to Treat Tumors II-69
    Nano-sized Polymers Offer Key Application in Treating Tumor
    Cells II-69
    Carbon Nanotubes Hold Promise in Development of Synthetic
    Muscular Tissues II-69
    Silicon Nanowires Offer Key Solutions to Cancer Detection and
    Diagnosis II-70
    Antigen Loaded Nanospheres Induce Immune Response II-70
    Tritons Nanotechnology Promises Potential Tool against Tumors II-70
    Carbon Nanotubes for Development of Advanced Biosensors II-71
    Scientists Develop New Technology to Produce Gold and Silver
    Nanoparticles II-71
    Scientists Develop Optical Biosensors from Single- Walled
    Carbon Nanotubes II-71
    Layer-by-Layer Nanoassembly Method for Nanocapsule Synthesis
    Gets Underway II-71
    Nanowires Prove Effective in Viruses Detection II-71
    Nanobiotechnology Enables SARS Test Development II-72

    9. Product Introductions/Developments II-73
    Evident Technologies Introduces Metal Quantum Dot Reagents II-73
    Abraxis Oncology Launches Novel Abraxane Drug Delivery System II-73
    Nanophase Introduces Novel Zinc Oxide Nanomaterial II-73
    ANP Technologies Develops Innovative Biological Detection System II-73
    Acrongenomics Introduces Innovative Cancer Detection Equipment II-74

    10.Recent Industry Activity II-75
    Invitrogen Acquires Quantum Dot Corporation II-75
    NABsys and Brown University Forge Partnership II-75
    University of Maryland Forges Partnership with University of
    Maryland Biotechnology Institute II-75
    ANP Technologies Partners with Cogent Systems II-75
    NCI forms Strategic Partnership with NSF II-75
    Debiopharm and Nanocarrier Ink Pact to Develop Platinum Anti
    Cancer Product II-76
    Capsulution and Ebara Sign Manufacturing Agreement for Nano-
    capsules II-76
    Invitrogen Licenses Nanoclusters Technology from Georgia Tech
    Research II-76
    Dendritic NanoTechnologies, Starpharma, and Dow Ink Pact II-76
    Dendritic Nanotechnologies Inks Collaboration Pact with NCL II-76
    Flamel Terminates Licensing Agreement with Biovail II-77
    MFIC Corporation and University of Massachusetts Sign
    Collaboration Pact II-77
    TAP Delivers Notice to Terminate Licensing Agreement with Flamel II-77
    Nanophase Inks Pact with Competitive Technologies II-77
    Infectech Changes Name to Nanologix II-77
    Arrowhead Establishes Nanobiotechnology Company II-78
    NCI Grants Funds to Establish Centers of Cancer Nanotechnology
    Excellence II-78
    Capsulution Bags Patents to Develop and Market Nano and
    Microstructures II-78
    Capsulution Receives Patent for Production of Novel Nano and
    Micro-Capsules II-78
    Carbon Nanotechnologies Wins 30 Patents for Small-diameter
    Carbon Nanotubes II-79
    Adnavance Technologies Receives Funding for M-DNA Technology II-79
    Angstrom Medica Wins FDA Approval for Nanoss™ Bone Void Filler II-79
    Carbon Nanotechnologies and C Sixty Merge II-79
    Capsulution and Nanosolutions to Join Forces II-79
    UK Institutions Forge Partnership to Develop Novel Therapy
    for Cancer II-80
    Triton and XOMA Sign Licensing Agreement II-80
    BioTrove Receives $11.1Million Funding to Develop
    Nanobiotechnology Products II-80
    Alnis Secures $2.71 Million Funding from NCI II-80
    Invitrogen Acquires Genicons RLS Technology II-80
    C Sixty Inks License, Option and Supply Agreement with Merck. II-81
    Alnis Wins Health Contract Award from NCI II-81

    11.Focus on Select Global Players II-82
    Alnis Biosciences, Inc. (USA) II-82
    American Pharmaceutical Partners, Inc. (USA) II-82
    Biosante Phosphate Pharmaceuticals, Inc. (USA) II-82
    Capsulution NanoScience AG (Germany) II-82
    Carbon Nanotechnologies, Inc. (USA) II-83
    C Sixty, Inc. (USA) II-83
    Dendritic Nanotechnologies, Inc. (USA) II-83
    Dendritech, Inc. (USA) II-83
    Elan Pharmaceuticals (USA) II-84
    Flamel Technologies, Inc. (France) II-84
    iMedd, Inc. (USA) II-84
    Nanospectra Biosciences, Inc. (USA) II-84
    Nanophase Technologies Corporation (USA) II-84
    Nano-C, Inc. (USA) II-85
    Nanocyl SA (Belgium) II-85
    Nanolab Systems Ltd. (Finland) II-85
    Nanosphere, Inc. (USA) II-85
    Nanotherapeutics, Inc. (USA) II-86
    Nanosys, Inc. (USA) II-86
    PSiVida Ltd (Australia) II-86
    Quantum Dot Corp. (USA) II-86
    Starpharma Holdings Ltd. (Australia) II-87
    Sigma Aldrich Company (USA) II-87
    Triton Biosystems, Inc (USA) II-87

    12.Global Market Perspective II-88
    Table 4: World Recent Past, Current & Future Analysis for
    Nanobiotechnology by Geographic Region
    USA, Japan, Europe,
    and Rest of World Markets Independently Analyzed with Annual
    Revenue Figures in US$ Million for Years 2000 through 2010
    (includes corresponding Graph/Chart) II-88

    Table 5: World 10-Year Perspective for Nanobiotechnology by
    Geographic Region
    Percentage Breakdown of Revenues for USA,
    Japan, Europe, and Rest of World for Years 2000, 2005 & 2010
    (includes corresponding Graph/Chart) II-88

    Table 6: World Recent Past, Current & Future Analysis for
    Nanomaterials by Geographic Region
    USA, Japan, Europe, and
    Rest of World Markets Independently Analyzed with Annual
    Revenue Figures in US$ Million for Years 2000 through 2010
    (includes corresponding Graph/Chart) II-89

    Table 7: World 10-Year Perspective for Nanomaterials by
    Geographic Region
    Percentage Breakdown of Revenues for USA,
    Japan, Europe, and Rest of World for Years 2000, 2005 & 2010
    (includes corresponding Graph/Chart) II-89

    Table 8: World Recent Past, Current & Future Analysis for
    Solid Inorganic Nanoparticles by Geographic Region
    USA,
    Japan, Europe, and Rest of World Markets Independently
    Analyzed with Annual Revenue Figures in US$ Million for Years
    2000 through 2010(includes corresponding Graph/Chart) II-90

    Table 9: World 10-Year Perspective for Solid Inorganic
    Nanoparticles by Geographic Region
    Percentage Breakdown of
    Revenues for USA, Japan, Europe, and Rest of World for Years
    2000, 2005 & 2010 (includes corresponding Graph/Chart) II-90

    Table 10: World Recent Past, Current & Future Analysis for
    Nanocomposites by Geographic Region
    USA, Japan, Europe, and
    Rest of World Markets Independently Analyzed with Annual
    Revenue Figures in US$ Million for Years 2000 through 2010
    (includes corresponding Graph/Chart) II-91

    Table 11: World 10-Year Perspective for Nanocomposites by
    Geographic Region
    Percentage Breakdown of Revenues for USA,
    Japan, Europe, and Rest of World for Years 2000, 2005 & 2010
    (includes corresponding Graph/Chart) II-91

    Table 12: World Recent Past, Current & Future Analysis for
    Nanostructured Materials & Membranes by Geographic Region -
    USA, Japan, Europe, and Rest of World Markets Independently
    Analyzed with Annual Revenue Figures in US$ Million for Years
    2000 through 2010 (includes corresponding Graph/Chart) II-92

    Table 13: World 10-Year Perspective for Nanostructured
    Materials & Membranes by Geographic Region
    Percentage
    Breakdown of Revenues for USA, Japan, Europe, and Rest of
    World for Years 2000, 2005 & 2010 (includes corresponding
    Graph/Chart) II-92

    Table 14: World Recent Past, Current & Future Analysis for
    Nanotubes and Fullerenes by Geographic Region
    USA, Japan,
    Europe, and Rest of World Markets Independently Analyzed with
    Annual Revenue Figures in US$ Million for Years 2000 through
    2010 (includes corresponding Graph/Chart) II-93

    Table 15: World 10-Year Perspective for Nanotubes and
    Fullerenes by Geographic Region
    Percentage Breakdown of
    Revenues for USA, Japan, Europe, and Rest of World for Years
    2000, 2005 & 2010 (includes corresponding Graph/Chart) II-93

    Table 16: World Recent Past, Current & Future Analysis for
    Other Nanomaterials by Geographic Region
    USA, Japan,
    Europe, and Rest of World Markets Independently Analyzed with
    Annual Revenue Figures in US$ Million for Years 2000 through
    2010 (includes corresponding Graph/Chart) II-94

    Table 17: World 10-Year Perspective for Other Nanomaterials
    by Geographic Region
    Percentage Breakdown of Revenues for
    USA, Japan, Europe, and Rest of World for Years 2000, 2005 &
    2010 (includes corresponding Graph/Chart) II-94

    Table 18: World Recent Past, Current & Future Analysis for
    Nanodevices/Tools by Geographic Region
    USA, Japan, Europe,
    and Rest of World Markets Independently Analyzed with Annual
    Revenue Figures in US$ Million for Years 2000 through 2010
    (includes corresponding Graph/Chart) II-95

    Table 19: World 10-Year Perspective for Nanodevices/Tools by
    Geographic Region
    Percentage Breakdown of Revenues for USA,
    Japan, Europe, and Rest of World for Years 2000, 2005 & 2010
    (includes corresponding Graph/Chart) II-95


    III. MARKET

    1. The United States III-1
    A.Market Analysis III-1
    Outlook III-1
    Industry Overview III-1
    Public Sector Funding III-1
    Major Nanobiotechnology Institutions and Centers III-2
    The Nanobiotechnology Center (NBTC) III-2
    Principal NBTC Partners III-3
    Centre for Biologic Nanotechnology (CBN) III-3
    Centre for Biological and Environmental Nanotechnology(CBEN) III-3
    Regulatory Environment III-4
    Technological Developments III-4
    Product Introductions/Developments III-7
    Strategic Corporate Developments III-8
    Key Players III-12
    B.Market Analytics III-17
    Table 20: US Recent Past, Current & Future Analysis for
    Nanobiotechnology by Technology Segment
    Nanomaterials
    (Solid Inorganic Nanoparticles, Nanocomposites,
    Nanostructured Materials & Membranes, Nanotubes and
    Fullerenes, Other Nanomaterials) and Nanodevices/Tools
    Markets Independently Analyzed with Annual Revenue Figures
    in US$ Million for Years 2000 through 2010 (includes
    corresponding Graph/Chart) III-17

    Table 21: US 10-Year Perspective for Nanobiotechnology by
    Technology Segment -Percentage Breakdown of Revenues for
    Nanomaterials (Solid Inorganic Nanoparticles,
    Nanocomposites, Nanostructured Materials & Membranes,
    Nanotubes and Fullerenes, Other Nanomaterials) and
    Nanodevices/Tools for Years 2000, 2005 & 2010 (includes
    corresponding Graph/Chart) III-18

    2. Japan III-19
    A.Market Analysis III-19
    Outlook III-19
    Public Sector Funding III-19
    Technological Development III-19
    B.Market Analytics III-20
    Table 22: Japanese Recent Past, Current & Future Analysis
    for Nanobiotechnology by Technology Segment
    Nanomaterials
    (Solid Inorganic Nanoparticles, Nanocomposites,
    Nanostructured Materials & Membranes, Nanotubes and
    Fullerenes, Other Nanomaterials) and Nanodevices/Tools
    Markets Independently Analyzed with Annual Revenue Figures
    in US$ Million for Years 2000 through 2010 (includes
    corresponding Graph/Chart) III-20

    Table 23: Japanese 10-Year Perspective for Nanobiotechnology
    by Technology Segment
    Percentage Breakdown of Revenues
    for Nanomaterials (Solid Inorganic Nanoparticles,
    Nanocomposites, Nanostructured Materials & Membranes,
    Nanotubes and Fullerenes, Other Nanomaterials) and
    Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes
    corresponding Graph/Chart) III-21

    3. Europe III-22
    A.Market Analysis III-22
    Outlook III-22
    Market Overview III-22
    European Union Banks Heavily on Nanobiotechnology III-22
    Nano2Life Network III-23 Major Nanobiotechnology
    Networks in Europe III-24
    Public Sector Funding III-24
    Table 24: European Nanobiotechnology Market (2003 & 2004):
    Percentage Breakdown of Public Sector Funding by Leading
    Region/Country
    European Commission, Germany, France, UK,
    and Others (includes corresponding Graph/Chart) III-25
    Regulatory Environment III-25
    Registration for Novel Nanobiotech Drugs Pose Major
    Bottlenecks III-25
    Focus on Select Markets III-26
    Germany III-26
    France III-26
    United Kingdom III-26
    Rest of Europe III-27
    Ireland III-27
    Market Overview III-27
    Key Research Institutions/Centers in Nanobiotechnology III-28
    The Tyndall National Institute III-28
    The Centre for Research on Adaptive Nanostructures and
    NanoDevices III-28
    The National Centre for Sensor Research III-28
    The Sami Nasr Institute for Advanced Materials Science III-28
    Technological Developments III-29
    Strategic Corporate Developments III-29
    Key Players III-31
    B.Market Analytics III-33
    Table 25: European Recent Past, Current & Future Analysis
    for Nanobiotechnology by Technology Segment
    Nanomaterials
    (Solid Inorganic Nanoparticles, Nanocomposites,
    Nanostructured Materials & Membranes, Nanotubes and
    Fullerenes, Other Nanomaterials) and Nanodevices/Tools
    Markets Independently Analyzed with Annual Revenue Figures
    in US$ Million for Years 2000 through 2010 (includes
    corresponding Graph/Chart) III-33

    Table 26: European 10-Year Perspective for Nanobiotechnology
    by Technology Segment
    Percentage Breakdown of Revenues
    for Nanomaterials (Solid Inorganic Nanoparticles,
    Nanocomposites, Nanostructured Materials & Membranes,
    Nanotubes and Fullerenes, Other Nanomaterials) and
    Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes
    corresponding Graph/Chart) III-34

    4. Rest of World III-35
    A.Market Analysis III-35
    Outlook III-35
    Public Sector Funding III-35
    Table 27: Nanobiotechnology Market in Rest of World (2004):
    Percentage Breakdown of Public Sector Funding by Leading
    Country
    South Korea, Taiwan, China, Australia, Canada,
    and Others (includes corresponding Graph/Chart) III-36
    Focus on Select Markets III-36
    Australia III-36
    Market Overview III-36
    Innovative Drug Delivery
    A Key Focus Area for Major
    Australian Companies III-36
    Nanobiotechnology Offers Major Breakthrough in HIV Drug
    Development III-37
    Major Institution III-37
    India III-38
    Market Overview III-38
    Korea III-38
    Market Overview III-38
    Table 28: Korean Nanobiotechnology Market (2003 & 2004):
    Funding in US$ Million by Major Organization Type -
    University Centers, Public Research Institution, and
    Companies (includes corresponding Graph/Chart) III-39
    Key Players III-39
    B.Market Analytics III-40
    Table 29: Rest of World Recent Past, Current & Future
    Analysis for Nanobiotechnology by Technology Segment -
    Nanomaterials (Solid Inorganic Nanoparticles,
    Nanocomposites, Nanostructured Materials & Membranes,
    Nanotubes and Fullerenes, Other Nanomaterials) and
    Nanodevices/Tools Markets Independently Analyzed with Annual
    Revenue Figures in US$ Million for Years 2000 through 2010
    (includes corresponding Graph/Chart) III-40

    Table 30: Rest of World 10-Year Perspective for
    Nanobiotechnology by Technology Segment
    Percentage
    Breakdown of Revenues for Nanomaterials (Solid Inorganic
    Nanoparticles, Nanocomposites, Nanostructured Materials &
    Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
    and Nanodevices/Tools for Years 2000, 2005 & 2010. (includes
    corresponding Graph/Chart) III-41


    IV. COMPETITION

    1. Abraxis Bioscience, Inc. (USA) IV-1
    Table 31: First Quarter Sales Analysis: 2005-2006 (Q1)
    (In US$ million) IV-2

    Table 32: First Quarter Sales Analysis by Product:
    2005-2006 (Q1) (In US$ million) IV-2

    Table 33: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-2
    Abraxis Oncology (USA) IV-2
    2. Acrongenomics, Inc. (Canada) IV-3
    3. Ademtech SA (France) IV-4
    4. Adnavance Technologies, Inc. (Canada) IV-5
    5. Advanced Micro/Nano Devices Lab (Canada) IV-6
    6. Advion Biosciences, Inc. (USA) IV-7
    7. Albany Molecular Research, Inc. (USA) IV-8
    Table 34: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-8
    8. Alnis Biosciences, Inc. (USA) IV-11
    9. Ambri Limited (Australia) IV-12
    Table 35: Half Yearly Sales Analysis: 2005-2006 (H1)
    (In A$ million) IV-13

    Table 36: Annual Sales Analysis: 2004-2005 (In A$
    million) IV-13

    Table 37: Annual Sales Analysis: 2003-2004 (In A$
    million) IV-13
    10. Angstrom Medica, Inc. (USA) IV-14
    11. ANP Technologies, Inc. (USA) IV-15
    12. Arrowhead Research Corporation (USA) IV-16
    Calando Pharmaceuticals, Inc. (USA) IV-16
    13. Asklepios Biopharmaceutical, Inc. (USA) IV-17
    14. BioDelivery Sciences International (USA) IV-18
    Table 38: Annual Sales Analysis: 2004-2005 (In US$
    million) IV-18
    15. BioForce Nanosciences, Inc. (USA) IV-20
    16. BioNano International Singapore Pte., Ltd. (Singapore) IV-21
    17. Biophage Pharma, Inc. (Canada) IV-22
    18. Biosante Pharmaceuticals, Inc. (USA) IV-24
    Table 39: Annual Sales Analysis: 2003-2005 (In US$
    thousand) IV-24

    Table 40: Annual Sales Analysis by Quarter: 2004-2005
    (In US$ thousand) IV-25
    19. Biotrove, Inc. (USA) IV-26
    20. Biovail Corporation (Canada) IV-28
    Table 41: First Quarter Sales Analysis: 2005-2006 (Q1)
    (In US$ million) IV-29

    Table 42: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-30

    Table 43: Annual Sales Analysis by Operation: 2004-2005
    (In US$ million) IV-30

    Table 44: Annual Sales Analysis by Geographic Region:
    2004-2005 (In US$ million) IV-30

    Table 45: Annual Sales Analysis by Operation: 2003-2004
    (In US$ million) IV-30

    Table 46: Annual Sales Analysis by Geographic Region:
    2003-2004 (In US$ million) IV-30
    21. Capsulution Nanoscience AG (Germany) IV-35
    22. Carbon Nanotechnologies, Inc. (USA) IV-37
    C Sixty, Inc. (USA) IV-39
    23. Cogent Systems, Inc. (USA) IV-40
    Table 47: First Quarter Sales Analysis: 2005-2006 (Q1)
    (In US$ million) IV-40
    Table 48: First Quarter Sales Analysis by Geographic
    Region: 2005-2006 (Q1) (In US$ million) IV-41
    Table 49: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-41

    Table 50: Annual Sales Analysis by Geographic Region:
    2004-2005 (In US$ million) IV-41

    Table 51: Annual Sales Analysis by Geographic Region:
    2003-2004 (In US$ million) IV-41
    24. Competitive Technologies, Inc. (USA) IV-45
    Table 52: Half Yearly Sales Analysis: 2005-2006 (H1)
    (In US$ million) IV-45
    Half Yearly Sales Analysis by Quarter: 2005-2006 (H1)
    (In US$ million) IV-46
    Table 53: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-46

    Table 54: Quarterly Sales Analysis: 2004-2005 (In US$
    million) IV-46

    Table 55: Quarterly Sales Analysis: 2003-2004 (In US$
    million) IV-46
    25. Concentris GmbH (Switzerland) IV-48
    26. Crystalplex Corporation (USA) IV-50
    27. CytImmune Science, Inc. (USA) IV-51
    28. Cytoplex Biosciences (USA) IV-52
    29. Debiopharm SA (Switzerland) IV-53
    30. Dendritech, Inc. (USA) IV-55
    31. Dendritic Nanotechnologies, Inc. (USA) IV-56
    32. Do-Coop Technologies Ltd. (Israel) IV-57
    33. Dow Nanotechnology (USA) IV-58
    34. Ebara Corporation (Japan) IV-59
    Table 56: Annual Sales Analysis: 2003-2005 (In ¥
    billion) IV-61

    Table 57: Annual Sales Analysis by Segment: 2004-2005
    (In ¥ billion) IV-61

    Table 58: Annual Sales Analysis by Geographic Region:
    2004-2005 (In ¥ billion) IV-61

    Table 59: Annual Sales Analysis by Segment: 2003-2004
    (In ¥ billion) IV-61

    Table 60: Annual Sales Analysis by Geographic Region:
    2003-2004 (In ¥ billion) IV-61
    35. Eiffel Technologies Ltd. (Australia) IV-63
    Table 61: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-63
    36. Elan Corporation PLC (Ireland) IV-65
    Table 62: First Quarter Sales Analysis: 2005-2006 (Q1)
    (In US$ million) IV-66

    Table 63: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-66

    Table 64: Annual Sales Analysis by Segment: 2004-2005
    (In US$ million) IV-66

    Table 65: Annual Sales Analysis by Geographic Region:
    2004-2005 (In US$ million) IV-67

    Table 66: Annual Sales Analysis by Segment: 2003-2004
    (In US$ million) IV-67

    Table 67: Annual Sales Analysis by Geographic Region:
    2003-2004 (In US$ million) IV-67
    Elan Pharmaceuticals (USA) IV-69
    37. Evident Technologies (USA) IV-70
    38. Exqor (USA) IV-71
    39. Flamel Technologies SA (France) IV-72
    Table 68: First Quarter Sales Analysis: 2005-2006 (Q1)
    (In US$ million) IV-73

    Table 69: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-73

    Table 70: Annual Sales Analysis by Quarter: 2004-2005
    (In US$ million) IV-73

    Table 71: Annual Sales Analysis by Quarter: 2003-2004
    (In US$ million) IV-73
    40. Fluidigm Corporation (USA) IV-76
    41. Genefluidics, Inc. (USA) IV-78
    42. Genencor International, Inc. (USA) IV-79
    Table 72: Annual Sales Analysis: 2003-2004 (In US$
    million) IV-80

    Table 73: Annual Sales Analysis by Segment: 2003-2004
    (In US$ million) IV-80

    Table 74: Quarterly Sales Analysis: 2003-2004 (In US$
    million) IV-80
    43. Georgia Tech Research Corporation (USA) IV-86
    44. Imedd, Inc. (USA) IV-86
    45. Integrated Nano-Technologies (USA) IV-87
    46. Interdisciplinary Research Collaboration In
    Bionanotechnology (IRC) (UK) IV-88
    47. Invitrogen Corporation (USA) IV-89
    Table 75: First Quarter Sales Analysis: 2005-2006 (Q1)
    (In US$ million) IV-90

    Table 76: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-90

    Table 77: Annual Sales Analysis by Quarter: 2004-2005
    (In US$ million) IV-90
    48. JPK Instruments AG (Germany) IV-96
    49. Kereos, Inc. (USA) IV-98
    50. Luna Innovations, Inc. (USA) IV-100
    51. MagnaMedics GmbH IV-103
    52. Merck & Co., Inc. (USA) IV-105
    Table 78: First Quarter Sales Analysis: 2005-2006 (Q1)
    (In US$ million) IV-106

    Table 79: First Quarter Sales Analysis by Product:
    2005-2006 (Q1) (In US$ million) IV-106

    Table 80: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-106

    Table 81: Annual Sales Analysis by Product: 2004-2005
    (In US$ million) IV-107

    Table 82: Annual Sales Analysis by Geographic Region:
    2004-2005 (In US$ million) IV-107

    Table 83: Annual Sales Analysis by Product: 2003-2004
    (In US$ million) IV-107

    Table 84: Annual Sales Analysis by Geographic Region:
    2003-2004 (In US$ million) IV-108
    53. MFIC Corporation (USA) IV-112
    Table 85: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-112

    Table 86: Annual Sales Analysis by Geographic Region:
    2004-2005 (In US$ million) IV-113

    Table 87: Quarterly Sales Analysis: 2004-2005 (In US$
    million) IV-113

    Table 88: Annual Sales Analysis by Geographic Region:
    2003-2004 (In US$ million) IV-113

    Table 89: Quarterly Sales Analysis: 2003-2004 (In US$
    million) IV-113
    54. Nabsys, Inc. (USA) IV-115
    55. Nacbo (Italy) IV-115
    56. Nano Interface Technology, Inc. (NITI) (USA) IV-116
    57. NanoBioMagnetics, Inc. (USA) IV-116
    58. NanoBioNexus (USA) IV-117
    59. Nanobiosym, Inc. (USA) IV-118
    60. Nano-C, Inc. (USA) IV-118
    61. NanoCarrier Co., Ltd. (Japan) IV-119
    62. Nanocyl SA (Belgium) IV-120
    63. Nanodisc, Inc. (USA) IV-121
    64. Nanodynamics, Inc. (USA) IV-122
    65. NanoLab, Inc. (USA) IV-126
    66. Nanolab Systems Ltd. (Finland) IV-126
    67. Nanolight Technologies (USA) IV-127
    68. Nanologix, Inc. (USA) IV-128
    69. NanoNord A/S (Denmark) IV-129
    70. Nanophase Technologies Corporation (USA) IV-130
    Table 90: First Quarter Sales Analysis: 2005-2006
    (Three Months Ended, March) (In US$ millions) IV-130

    Table 91: First Quarter Sales Analysis By Operations:
    2005-2006 (Three Months Ended, March) (In US$ millions) IV-131

    Table 92: Annual Sales Analysis: 2003-2005 (In US$
    millions) IV-131

    Table 93: Annual Sales Analysis By Operations: 2004-
    2005 (In US$ millions) IV-131

    Table 94: Annual Sales Analysis By Operations: 2003-
    2004 (In US$ millions) IV-131

    Table 95: Quarterly Sales Analysis: 2004-2005 (In US$
    millions) IV-131

    Table 96: Quarterly Sales Analysis: 2003-2004 (In US$
    millions) IV-132

    71. Nanoplex Technologies, Inc. (USA) IV-135
    72. Nanoprobes, Inc. (USA) IV-136
    73. Nanosolutions GmbH (Germany) IV-137
    74. Nanospectra Biosciences, Inc. (USA) IV-137
    75. Nanosphere, Inc. (USA) IV-138
    76. Nanosys, Inc. (USA) IV-139
    77. Nanotherapeutics, Inc. (USA) IV-142
    78. Nanoxis AB (Sweden) IV-143
    79. National Physical Laboratory (UK) IV-144
    80. Platypus Technologies, LLC (USA) IV-146
    81. Proteinx Lab (USA) IV-147
    82. PSiVida Ltd. (Australia) IV-148
    83. Sigma-Aldrich Corporation (USA) IV-149
    Table 97: First Quarter Sales Analysis: 2005-2006 (Q1)
    (In US$ million) IV-150

    Table 98: Annual Sales Analysis: 2003-2005 (In US$
    million) IV-150

    Table 99: Quarterly Sales Analysis: 2004-2005 (In US$
    million) IV-150

    Table 100: Annual Sales Analysis by Segment: 2004-2005
    (In US$ million) IV-150

    Table 101: Annual Sales Analysis by Geographic Region:
    2004-2005 (In US$ million) IV-151

    Table 102: Quarterly Sales Analysis: 2003-2004 (In US$
    million) IV-151

    Table 103: Annual Sales Analysis by Segment: 2003-2004
    (In US$ million) IV-151

    Table 104: Annual Sales Analysis by Geographic Region:
    2003-2004 (In US$ million) IV-151
    84. SRU Biosystems, Inc. (USA) IV-158
    85. Starpharma Holdings Limited (Australia) IV-159
    Table 105: Half Yearly Sales Analysis: 2005-2006 (H1)
    (In A$ million) IV-159

    Table 106: Annual Sales Analysis: 2003-2005 (In A$
    million) IV-160

    Table 107: Annual Sales Analysis by Segment: 2004-2005
    (In A$ million) IV-160

    Table 108: Annual Sales Analysis by Segment: 2003-2004
    (In A$ million) IV-160
    86. Tap Pharmaceutical Products, Inc. (USA) IV-162
    87. Triton Biosystems, Inc. (USA) IV-163
    88. U.S. Genomics, Inc. (USA) IV-164
    89. Visigen Biotechnologies, Inc. (USA) IV-168
    90. Vulvox Nano/Biotechnology Corporation (USA) IV-169
    91. Xoma Ltd. (USA) IV-170
    Table 109: Annual Sales Analysis: 2004-2005 (In US$
    thousand) IV-170

    Table 110: Annual Sales Analysis by Segment: 2004-2005
    (In US$ thousand) IV-170

    Table 111: Annual Sales Analysis by Geographical
    Region: 2004-2005 (In US$ thousand) IV-170
     

    (来源: 互联网 )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 山西快乐十分开奖视频 老11选5图表 大乐透走势图图带坐标 福建11选5走势图浙 平特论坛三肖中特 北京pk10冠军直播 江西快三追号计划 体彩p5号码预测软件 北京pk赛车官网 老大爷梭哈表情包 第一比分网 彩票客户端 云南快乐十分 彩票云南11选5开奖查询结果 宁夏11选5手机号